Alphabet Inc Class A vs Merck & Co., Inc. — how do they compare? Alphabet Inc Class A trades at $372.32 (market cap $4.52T), while Merck & Co., Inc. trades at $127.71 (market cap $305.29B). The key difference: Alphabet Inc Class A is far larger — about 14.8× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.75%). Which is the better fit depends on your goals.
| GOOGL | MRK | |
|---|---|---|
Market Cap | $4.52T | $305.29B |
Sector | Media | Health |
52-Week High | $402.62 | $129.52 |
52-Week Low | $182.97 | $77.60 |
Enterprise Value | $4.49T | $348.71B |
Dividend Yield | 0.24% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $359.51, up 1.99% on the day, with a neutral technical signal but bullish moving averages. The company demonstrates strong fundamentals with revenue growing to $402.84B in 2025 and net income surging to $132.17B, yielding a 32.8% profit margin. Recent earnings have consistently beaten expectations, and the company initiated its first dividend. Analyst sentiment remains overwhelmingly positive with an 85% buy rating and a $431.78 consensus price target, suggesting significant upside potential from current levels.
The outlook for GOOGL is positive, driven by robust earnings growth, expanding AI integration across its ecosystem, and strong cash flow generation. Key opportunities include leadership in AI infrastructure, monetization of YouTube and cloud services, and strategic investments like SpaceX. Primary risks involve regulatory scrutiny, intense competition in AI and cloud computing, and potential market volatility. The stock's current valuation, while elevated, is supported by its growth trajectory and dominant market position.
Merck (MRK) trades at $120.80, down 2.6% on the day, with technical indicators showing a bullish moving average signal but neutral oscillators. The company reported strong recent earnings beats and maintains solid profitability with a 73.91% gross margin and 13.59% net margin. Recent news highlights Merck's acquisition of Terns Pharmaceuticals for approximately $6.7 billion to bolster its oncology pipeline, while institutional investors continue accumulating shares.
The outlook remains positive with analyst consensus at Buy (67.57%) and a $137.30 price target, suggesting 13.7% upside. Key risks include integration challenges from the Terns acquisition, competitive pressures in oncology, and potential regulatory headwinds. Strong cash flow generation ($16.47B operating cash flow in 2025) supports continued dividend payments and strategic investments.
Trailing returns across standard periods
Latest headlines on both assets
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →